MEDIAN Technologies Signs a ?384K Contract with a San Francisco-area Biotech Company

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced that it has signed a contract with a San Francisco-area based biotech company. The contract amount is €384,000 (eq. $ 524,500).

MEDIAN Technologies will provide imaging services to support a phase II clinical trial for advanced non-small cell lung cancer. Within the framework of the study, imaging data will be acquired from 90 clinical sites, based in 12 European countries, in the US, and in Canada. Anticipated total enrollment is 440 patients with a "first patient in" forecasted May, 2014. MEDIAN will supply a set of services including clinical site qualification and training, as well as image and data collection, quality control, and storage.